Last10K.com

Numed Plus, Inc. (NUMD) SEC Filing 8-K Material Event for the period ending Tuesday, June 27, 2017

Numed Plus, Inc.

CIK: 1543637 Ticker: NUMD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549



FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


June 27, 2017

(Date of Report: Date of earliest event reported)



NU-MED PLUS, INC.

(Exact name of registrant as specified in its charter)


Utah

000-54808

45-3672530

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer ID No.)


455 East 500 South, Suite 203, Salt Lake City, Utah 84111

 (Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (801) 746-3570



N/A

 (Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[ ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter or Rule 12b-2 of the Securities and Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company  x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨







SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS


This document contains forward-looking statements, which reflect our views with respect to future events and financial performance. These forward-looking statements are subject to certain uncertainties and other factors that could cause actual results to differ materially from such statements. These forward-looking statements are identified by, among other things, the words “anticipates,” “believes,” “estimates,” “expects,” “plans,” “projects,” “targets” and similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Important factors that may cause actual results to differ from those projected include the risk factors specified below.


Item 7.01 Regulation FD Disclosure.


See Item 9.01, Exhibit 99.


The information contained in this Item 7.01 and in Exhibit 99 is being furnished, and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to liability under such Section 18.  Furthermore, the information contained in this Item 7.01 and in Exhibit 99 shall not be deemed to be incorporated by reference into our filings under the Securities Act or the Exchange Act.


Item 9.01 Financial Statements and Exhibits.


(a)

Exhibits.


Exhibit No.

Description


99

Press Release dated June 27, 2017.



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunder duly authorized.


NU-MED PLUS, INC.



By: /s/ Jeffrey L. Robins

Date: June 28, 2017

      Jeffrey L. Robins, CEO




View differences made from one to another to evaluate Numed Plus, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Numed Plus, Inc..

Continue

Assess how Numed Plus, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Numed Plus, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2017 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Material Contracts, Statements, Certifications & more

Numed Plus, Inc. provided additional information to their SEC Filing as exhibits

Ticker: NUMD
CIK: 1543637
Form Type: 8-K Corporate News
Accession Number: 0001548123-17-000154
Submitted to the SEC: Wed Jun 28 2017 3:39:11 PM EST
Accepted by the SEC: Wed Jun 28 2017
Period: Tuesday, June 27, 2017
Industry: Surgical And Medical Instruments And Apparatus
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/numd/0001548123-17-000154.htm